MS researchers find decline in cognitive performance for people with multiple sclerosis as outdoor temperatures rise

 

Results have implications for patients and researchers

 

West Orange, N.J. (March 13, 2012) – Kessler Foundation scientists have shown for the first time that outdoor temperature significantly affects cognitive functioning in multiple sclerosis (MS). While it is recognized that disease activity increases during warmer months, this is the first study to document that cognition also fluctuates. During warmer outdoor temperatures patients with MS performed worse on tasks involving processing speed and memory. An estimated 50 to 65% of people with MS experience problems with thinking, learning and remembering that can be disabling.

 

Warmer outdoor temperature is associated with worse cognitive status in MS,” was published online ahead of print by Neurology. An accompanying editorial, “MS and heat: The smoke and the fire,” discusses the study’s contributions to understanding MS. According to the results, cognitive performance may be a more sensitive indicator of subclinical disease activity than traditional assessments.

 

In the study, which spanned the calendar year, 40 individuals with MS and 40 people without MS underwent cognitive assessment of memory and processing speed. People with MS scored 70 percent higher on cooler days; no association was found for individuals without MS. Funding was provided by the National MS Society and the NIH.

 

According to Victoria M. Leavitt, Ph.D., research scientist, and the study’s principal investigator, these findings have implications for patients, clinicians and researchers. “This information is relevant to making life decisions and choosing therapies and evaluating their effects,” said Dr. Leavitt. “Outdoor temperatures may be an important consideration when designing and conducting clinical trials, many of which span six months.” For example, taking baseline measurements during warmer months could inflate positive findings. The study’s co-investigators are James F. Sumowski, Ph.D., Research Scientist, Nancy Chiaravalloti, Ph.D., Director of Neuropsychology & Neuroscience Research, and John DeLuca, Ph.D., VP for Research.

 

Kessler Foundation is nationally and internationally known for cognitive rehabilitation research in MS and traumatic brain injury. Its neuroscience research supports the theory of cognitive reserve, ie, people with MS who lead intellectually enriching lives are less likely to experience cognitive decline. A recent publication documented changes in brain activity on fMRI associated with effective memory retraining in people with MS.

 

 

About Kessler Foundation

 

Kessler Foundation, the largest public charity in the field of disability, conducts rehabilitation research in mobility and cognition that advances the care of people with multiple sclerosis, brain injury, stroke and spinal cord injury. Kessler Foundation Program Center fosters new approaches to the persistently high rates of unemployment among people disabled by injury or disease.  

 


Kessler Foundation, 13.03.2012 (tB).

MEDICAL NEWS

Inadequate sequencing of SARS-CoV-2 variants impedes global response to COVID-19
New meta-analysis finds cannabis may be linked to development of…
New guidance on how to diagnosis and manage osteoporosis in…
Starting the day off with chocolate could have unexpected benefits
Better mental health supports for nurses needed, study finds

SCHMERZ PAINCARE

Versorgung verbessern: Deutsche Gesellschaft für Schmerzmedizin fordert die Einführung des…
Pflegeexpertise im Fokus: Schmerzmanagement nach Operationen
Versorgung verbessern: Bundesweite Initiative der Deutschen Gesellschaft für Schmerzmedizin zu…
Jedes vierte Kind wünscht bessere Schmerzbehandlung
Lebensqualität von Patienten in der dauerhaften Schmerztherapie mit Opioiden verbessern

DIABETES

Bundestag berät über DMP Adipositas: DDG begrüßt dies als Teil…
Mit der Smartwatch Insulinbildung steuern
Verbände fordern bessere Ausbildung und Honorierung von Pflegekräften für Menschen…
Minimalinvasive Geräte warnen ungenügend vor Unterzuckerung
Typ-1-Diabetes und Hashimoto-Thyreoiditis treten häufig gemeinsam auf

ERNÄHRUNG

Wie eine Diät die Darmflora beeinflusst: Krankenhauskeim spielt wichtige Rolle…
DGEM plädiert für Screening und frühzeitige Aufbautherapie: Stationäre COVID-19-Patienten oft…
Führt eine vegane Ernährungsweise zu einer geringeren Knochengesundheit?
Regelmässiger Koffeinkonsum verändert Hirnstrukturen
Corona-Erkrankung: Fehl- und Mangelernährung sind unterschätze Risikofaktoren

ONKOLOGIE

Anti-Myelom-Therapie mit zusätzlich Daratumumab noch effektiver
Positive Ergebnisse beim fortgeschrittenen Prostatakarzinom: Phase-III-Studie zur Radioligandentherapie mit 177Lu-PSMA-617
Lymphom-News vom EHA2021 Virtual. Alle Berichte sind nun online verfügbar!
Deutsch-dänisches Interreg-Projekt: Grenzübergreifende Fortbildungskurse in der onkologischen Pflege
Sotorasib: Neues Medikament macht Lungenkrebs-Patienten Hoffnung

MULTIPLE SKLEROSE

NMOSD-Erkrankungen: Zulassung von Satralizumab zur Behandlung von Jugendlichen und Erwachsenen
Verzögerte Verfügbarkeit von Ofatumumab (Kesimpta®)
Neuer Biomarker bei Multipler Sklerose ermöglicht frühe Risikoeinschätzung und gezielte…
Multiple Sklerose beginnt oft lange vor der Diagnose
Goldstandard für Versorgung bei Multipler Sklerose

PARKINSON

Meilenstein in der Parkinson-Frühdiagnose
Parkinson-Erkrankte besonders stark von Covid-19 betroffen
Gangstörungen durch Kleinhirnschädigung beim atypischen Parkinson-Syndrom
Parkinson-Agenda 2030: Die kommenden 10 Jahre sind für die therapeutische…
Gemeinsam gegen Parkinson: bessere Therapie durch multidisziplinäre Versorgung